Eva Schaefer-Jansen | Head, IR |
Paul Hudson | CEO |
Jean-Baptiste de Chatillon | EVP & CFO |
Bill Sibold | EVP, Sanofi Genzyme and President, Sanofi North America |
John Reed | EVP & Global Head, Research & Development |
Thomas Triomphe | Head, Vaccines |
Olivier Charmeil | EVP, General Medicines |
Julie Van Ongevalle | EVP, Consumer Healthcare |
Wimal Kapadia | Sanford C. Bernstein |
Jo Walton | Crédit Suisse |
Graham Parry | Bank of America Securities |
Richard Vosser | J.P. Morgan |
David Risinger | SVB Leerink Securities |
Mark Purcell | Morgan Stanley |
Keyur Parekh | Goldman Sachs |
Timothy Anderson | Wolfe Research |
Laura Sutcliffe | UBS |
Unidentified Analyst | BNP Paribas Exane |
Simon Baker | Redburn |
Seamus Fernandez | Guggenheim Securities |
Peter Verdult | Citigroup |
Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's 2022 Second Quarter Results followed by a Q&A session.
As usual, you can find the slides to this earnings call on the Investors page of our website at sanofi.com.
Moving to Slide 3, I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors.